Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Ann Jefferds

Pulmonary Disease Salt Lake City, UT Medical Doctor

NPI 1386691558 CMS profile 1199751

University Of Utah Medical Center 50 North # 160, Salt Lake City, UT 84132

Open in the dashboard

General payments

$8,692

515 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Ann Jefferds of Salt Lake City, UT is reported in the CMS Open Payments database as having received $8,692 across 515 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 77th percentile of Pulmonary Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,061 113
2024 General $2,181 125
2023 General $1,850 116
2022 General $1,361 80
2021 General $483 30
2020 General $304 20
2019 General $452 31

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ann Jefferds
  • Pulmonary Disease median
  • Middle half of Pulmonary Disease
  • National median

In program year 2025, general payments to Ann Jefferds were reported at $2,061. Among 8,914 Pulmonary Disease profiles paid that year, the median was $500 and the middle half received between $124 and $1,893.

Show as a table
Year Ann Jefferds Pulmonary Disease median Middle half National median
2019 $452 $377 $109–$1,340 $163
2020 $304 $230 $56–$907 $114
2021 $483 $269 $68–$1,072 $132
2022 $1,361 $390 $100–$1,457 $149
2023 $1,850 $419 $114–$1,659 $160
2024 $2,181 $476 $123–$1,818 $164
2025 $2,061 $500 $124–$1,893 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $798 38 payments
  2. Lilly USA, LLC $729 46 payments
  3. Amgen Inc. $685 46 payments
  4. Pfizer Inc. $684 55 payments
  5. ViiV Healthcare Company $563 30 payments
  6. Boehringer Ingelheim Pharmaceuticals, Inc. $506 23 payments
  7. Gilead Sciences, Inc. $460 22 payments
  8. Astellas Pharma US Inc $359 22 payments
  9. GlaxoSmithKline, LLC. $350 23 payments
  10. Merck Sharp & Dohme Corporation $332 21 payments
  11. Other $3,225 189 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $8,692 515 payments
Products named General payments · program years 2019–2025
  1. MOUNJARO $471 29 payments
  2. APRETUDE $418 24 payments
  3. NURTEC ODT $383 28 payments
  4. UBRELVY $373 19 payments
  5. Otezla $327 25 payments
  6. ZAVZPRET $322 23 payments
  7. QULIPTA $318 16 payments
  8. Veozah $280 16 payments
  9. Kerendia $279 15 payments
  10. Repatha $265 19 payments
  11. Other $8,247 510 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 94 drugs

Part D claims

4,148

Median for Internal Medicine: 777

Drug cost

$315,958

Median for Internal Medicine: $73,373

Branded share of claims

20.9%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 67 $76,677
Ozempic Semaglutide Brand 53 $56,169
Eliquis Apixaban Brand 40 $43,354
Mounjaro Tirzepatide Brand 16 $18,873
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 14 $15,037
Jardiance Empagliflozin Brand 11 $13,782
Stiolto Respimat Tiotropium Br/Olodaterol Hcl Brand 11 $9,190
Symbicort Budesonide/Formoterol Fumarate Brand 17 $6,194
Budesonide-Formoterol Fumarate Budesonide/Formoterol Fumarate Brand 15 $5,258
Movantik Naloxegol Oxalate Brand 12 $5,021

The 10 drugs with the highest cost, of 94 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 34 billing codes

Paid by Medicare

$43,034

Medicare's payments for the services billed

Medicare patients

162

Average age 74

Services billed

670

116 women, 46 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 73%
Arthritis 47%
Depression 40%
Chronic kidney disease 25%
Ischemic heart disease 24%
Diabetes 18%
COPD 17%
Cancer 14%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 33 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
MOUNJARO
  • Lilly USA, LLC $172
$172 16 —
APRETUDE
  • ViiV Healthcare Company $169
$169 — —
UBRELVY
  • AbbVie, Inc. $144
$144 — —
VRAYLAR
  • AbbVie, Inc. $139
$139 — —
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $60
  • Lilly USA, LLC $51
$111 11 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 33 with Patron

Records

515 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pulmonary Disease in Utah

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record